 NOTICE OF APPROVAL FOR HUMAN RESEARCH
DATE:  	
 
TO: 
 
    

  
    
 !
 
    
 
 "
FROM: #
 $ 
 %& ' 
PROTOCOL TITLE:( )*     )   ++ # (+ , - .$
/  0
FUNDING SOURCE: 1 23
PROTOCOL NUMBER: 4/4456
APPROVAL PERIOD: -++$ 7,  6
 
 + 7,  8
 5
 %& ' $#  9':   +  ) .*  $#  + , ( )*    
)   ++ # (+ , - .$ /  00  +*  . ++$   +  .*
.   +0  + ) . $#  #     .   3    ) $0   +
 . # . +
  $ )    +  . /$#0
')+ ), '   #    ++ #  3  )
     +.     )   .
;  +      < .  ' 0 2    ;  ) $.    
<   +. + $0
' ++$   )+  ++ #  # .)   +
    <'= +.  +$  + #  ++$ 0
 ++$    %  &$ = 2 > - 48
 #  1  )  < 91<:0 '
  $  ? 33   .3  %&= -
 +      0
<   ? .  '=    +* ,
' 1 / 9	
: 8	/66@A '%1B'C)0%0
$  #
  ' % / 9	
: 8	/@5A $ 0#C%0
)) 2/D 
 - ' % / 9	
: 8	/466A )) 02/D C%0
#
 $ 
%3 #  . $#   $ )3   6
 
0 %  . ++$    )3 @8 98
$ A   : ++ #  ++$ )   +0 -++$ ) , % %
 $
Research Integrity & Compliance Review Office
Office of the Vice President for Research
321 General Services Building - Campus Delivery 2011 eprotocol
TEL: ([PHONE_6011]
FAX: ([PHONE_6012]
 	
  ( 
A (( %
 $  ( 
0
BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
Approval Period:  6
 
 3  8
 5
Review Type: 2&""1-7
IRB Number: 845
Funding: %& %#3 %3
Research Integrity & Compliance Review Office
Office of the Vice President for Research
321 General Services Building - Campus Delivery 2011 eprotocol
TEL: ([PHONE_6011]
FAX: ([PHONE_6012]
 

 PROTOCOL
Biomedical
Colorado State
UniversityProtocol # 16-6685HH
 Date Printed: 07/18/[ADDRESS_353343] 5
Funding 6
Expedited Paragraphs 7
Purpose,Study Procedures,Background 8
Radioisotopes or Radiation Machines 11
Medical Equipment for Human Subjects and Laboratory Animals; Investigatiional Devices [ADDRESS_353344] Population (a-g) [ADDRESS_353345] Population (h-m) [ADDRESS_353346] 18
Informed Consent 19
Assent Background 19
HIPAA 20
Attachments 21
 PROTOCOL
Biomedical
Colorado State
UniversityProtocol # 16-6685HH
 Date Printed: 07/18/2018
Obligations 24
Event History 24
Page 1 of 25
 1PROTOCOL
Biomedical
Colorado State
UniversityProtocol # 16-6685HH
 Date Printed: 07/18/2018
Protocol Title: Medical marijuana and its effects on motor function in people with Multiple Sclerosis: An
observational case-control study.
Protocol Type: Biomedical
Date Submitted: 06/06/2017
Approval Period: Draft
Important Note: This Print View may not reflect all comments and contingencies for approval. Please check the
comments section of the online protocol.
Questions that appear to not have been answered may not have been required for this submission.
Please see the system application for more details.
----------------------------------------------------------------------------------------------------
* * * Continuing review * * *
 
To renew your protocol: 1. Complete this one-page form; 2.  If necessary, update any sections of the protocol
that need to be updated for the upcoming year (e.g., change in personnel, location); 3. Electronically "sign" the
application by [CONTACT_152618] "Obligations" page; 4.  Remember to click "Submit
Form" and confirm your intent to submit by [CONTACT_18943] "OK" so that the IRB administrators receive your application.
You must answer each question. Input N/A to answer any questions that are not applicable.  NOTE:  Documents
that contain much of the information required to answer the participant number questions below can be found in
the "Event History" section of each protocol.  The status on your homepage will be "Submitted to IRB" when your
submission is successful. IMPORTANT:   If the Department Head has changed since your last approval, please
be sure to update the Department Head listing on the personnel Information screen of your protocol.
 
1. Summary: Number of Participants Associated with the Protocol:Â 
Â 
Â Â  Â Â  Â a.Â  Total number of participants approved to date:
40 (20 MS users; 20 MS non users)
 
Â Â  Â Â  Â b.Â  Number of participants studied since the last approval date:
6 (all MS users)
 
Â Â  Â Â  Â c.Â  Total number of participants studied since the beginning of the project:
6
 
Â Â  Â Â  Â d.Â  Number of participants remaining to study (total number of participants approved  LESS  the
total number of participants studied to date):
34
(14 MS users; 20 MS non users)
 
Â Â  Â Â  Â e.Â  Please explain if there is a discrepancy in participant numbers (e.g., more participants
responded to a survey than had been approved):
N/A
 
 
2. Â a.Â  Reasons and number of withdrawals from the research (both subject and investigator initiated)
since the last approval date.
Page [ADDRESS_353347] to follow-up since the beginning of the study.
N/A
 
Â Â  Â Â  Â c.Â  Please summarize any protocol deviations/violations or unanticipated problems (UPs)/adverse
events (AEs) since the last continuing review or original approval (if this is your first continuing
review).  Please indicate if any of the unanticipated problems/events are being reported to the
IRB for the first time.  If you have or will make changes to your protocol as a result of any
unanticipated problem/event or adverse event, please summarize those changes in Question #[ADDRESS_353348] year.
none
 
3. A summary of any recent findings, literature, or other relevant information (especially pertaining to
risks), if applicable.
N/A
 
4. Description of the remainder of project:
Y Do you plan to recruit more subjects?
Â 
If "No," have all subjects completed all research-related interventions?  Note: Protocols must be
renewed to continue recruiting participants and/or collect data from already recruited participants.
Â 
N Are you only performing data analysis?  NOTE:  If you are analyzing data with no identifiers (i.e., you
cannot link your data to individuals), you can close your protocol by [CONTACT_17258] a Final Report.
 
N Does this protocol have a Data Satety Monitoring Board (DSMB)?
 
If you do have a DSMB, have reports been submitted to the IRB and/or the Sponsor?
Upload any DSMB reports that have not yet been submitted to the IRB since the approval
or last continuing review.
Â 
5. Summarize all approved changes in the protocol since the last continuing review or since the original
approval (if this is your first continuing review).  For example: Have you amended your protocol
during the past year?  Are you requesting to make any changes for the upcoming year?  Have you
included any changes as a result of an unanticipated problem/event or Adverse events (AE)?  Have
there been any personnel changes in the past year (including a change in department head)?
balance test changed - legged test to two legged test (mCTSIB)
No Rate of Force Development tests performed
Order tests in each visit changed
 
Â Â Â Â Â Â Â Â Â 
If necessary, proceed to the appropriate section(s) of the protocol and make your requested changes.
Remember that if you are requesting to revise a document that is already attached, you must delete the
already attached document and upload the revised document.
 
Page [ADDRESS_353349] of Protocol Sections (and questions) that have been changed/modified.
N/A
---------------------------------------------------------------------------------------------
* * * Personnel Information * * *
IMPORTANT NOTE: Mandatory Personnel on a protocol are: Principal Investigator [INVESTIGATOR_152605]. Only
the Principal Investigator [INVESTIGATOR_152606]; although other personnel listed on the protocol can create the
protocol. Human Subjects Protection Training is mandatory for Principal Investigator, Co-Principal Investigator,
and Key Personnel (as defined by [CONTACT_4289]). Training must be updated every three (3) years.
 
Principal Investigator  [INVESTIGATOR_152607]
(Faculty, Staff or Postdoc)Degree Title
Rudroff, Thorsten Assistant [CONTACT_152672]
[EMAIL_3125] ([PHONE_3424]
Department Name [CONTACT_289660]? PIs must complete training every three
(3) years.Y
 
CO-Principal Investigator
[INVESTIGATOR_152608]-Principal Investigator
(This could be another faculty or a
Master's or Ph.D. student)Degree Title
Kindred, John Graduate Assistant
Email Phone Fax
[EMAIL_3126]
Department Name [CONTACT_289660]? Training is required for Co-PI. Training
must be updated every three (3) years.Y
No training data is available.
 
 
Department Head  Mandatory
Name [CONTACT_152651], Barry [CONTACT_152672]
[EMAIL_3129] ([PHONE_3425]
Department Name [CONTACT_289660]?? Training is not required for
Department Head. Select "No" if you do not know if your Department Head has
completed training or not.Y
 
Administrative Contact
[CONTACT_3490] [ADDRESS_353350] Director, or Lab CoordinatorDegree: Title
Biela, Laurie
Email Phone Fax
[EMAIL_3130]
Department Name [CONTACT_152649] Â 
244 Â 
 Human Subjects Training Completed? Training is not required for
Administrative Contact[CONTACT_289657].
 
---------------------------------------------------------------------------------------------
* * * Subject Population * * *
 
 
Subject Population(s) Checklist
Â Â Â Â Â Â Â  Ã‚Â Select All That Apply - Note that this is your Targeted Population :
X Â Adult Volunteers
Â Decisionally Challenged
Elderly
Â Employees
Â Fetuses
X Â Long-Term Patients
Â Mentally Disabled
Â Minors (under 18)
Â Pregnant Women
Â Prisoners
Â Soldiers
Â Students
Â Other (i.e., non-English Speaking or any population that is not specified above)
Â Â Â Â Â Â Â 
---------------------------------------------------------------------------------------------
* * * Study Location * * *
 
 
Study Location(s) Checklist
Â Â Â Â Â Â Â  Â Select All That Apply - NOTE: Check "Other" and input text: 1.) If your study location is not listed, or 2.) If
you would like to list details of your already-checked location (e.g., specific school within a school district)
Aims Community College
Colorado Department of Public Health & Environment
X Colorado State University
Colorado State University - Pueblo Campus
Denver Public Schools
Greeley/Evans School District
Poudre School District
University of Colorado Health - North (Formerly -Poudre Valley Health System - PVHS)
Rocky Mountain National Park
Thompson School District
Page 5 of 25
 University of Colorado - Boulder
University of Colorado - Colorado Springs
University of Colorado - Denver
University of Colorado Health Sciences Center
University of Northern Colorado
Other (In the box below, list your study location if not checked above. You may also list details of your
already-checked location (e.g., specific school within a school district).
Â Â Â Â Â Â Â 
---------------------------------------------------------------------------------------------
* * * General Checklist * * *
 
General Checklist
Â Â Â Â Â Â Â  Â Select All That Apply :
X Proposed Start Date (cannot be before IRB approval): August [ADDRESS_353351] (Check if you will be funded OR if you have or plan to submit a grant application in
association with this protocol)
NSF Sponsored (Please upload mandatory Data Management Plan in the Attachment section)
FDA or EPA-regulated research.  Please contact [CONTACT_152620], Cat Bens, at 970-
491-5445 to determine if your study is under Good Laboratory, Good Clinical, or Good Manufacturing
Practices (GLP, GCP, GMP).
Â Training Grant
Clinical Trial.  To register your trial on Clinicaltrials.gov, please contact [CONTACT_152621], CSU Quality Assurance
Manager and Clinical Trails Administrator at:  [PHONE_3426].
Project is associated with the Colorado School of Public Health - CSPH(faculty and/or student)
Cooperating/Collaborating Institution(s) Institution
where recruitment will occur OR Institution where
Collaborating PI [INVESTIGATOR_152612].
Interview
X Questionnaire/Survey
X Â Subjects will be compensated for participation
Thesis or Dissertation Project
ÃƒÃ‚Â Radioisotopes/radiation-producing machines, even if standard of care.  Please contact [CONTACT_152622],
Radiation Safety Officer for questions related to use of all radiation-producing machine:  [PHONE_3427];
[EMAIL_3131].  Upload your radiation-use approval  (if available) or your Radiation Safety
Training certificate in the attachment section.
X Human blood, cells, tissues, or body fluids. You will need to obtain IBC approval if you check this box. For
information regarding IBC approval, contact [CONTACT_152623], IBC Coordinator:
[EMAIL_3132]
Â Tissues to be stored for future research projects
Â Tissues to be sent out of this institution as part of a research agreement
Human Embryos. You will need to obtain IBC approval if you check this box. For information regarding IBC
approval, contact [CONTACT_152623], IBC Coordinator:  [EMAIL_3132]
Human Embryonic Cells? Provide NIH Code Number(s)
or state that no federal funding will be used to support
this research. You may need to obtain IBC approval if
you check this box. For information regarding IBC
approval, contact [CONTACT_152623], IBC Coordinator:
[EMAIL_3132]
Â Use of Patient-related equipment? If Yes, specify what equipment is being used.
Medical equipment used for human patients/subjects also used on animals. For questions regarding animal
Page [ADDRESS_353352] Elaine Kim, IACUC Senior Coordinator:  491-[ADDRESS_353353] Chris Giglio, DRC Coordinator:  491-4830; [EMAIL_3133].
Investigational drugs, reagents, or chemicals (IND)
Â Commercially available drugs, reagents, or other chemicals administered to subjects (even if they are not
being studied)
Investigational Device (IDE)
Cancer Subjects (e.g., clinical trials, behavior/prevention) or Cancer Tissues (e.g., blood, cells, body fluids).
You may need to obtain IBC approval if you check this box. For information regarding IBC approval, contact
[CONTACT_152623], IBC Coordinator:  [EMAIL_3132]
Other (clarify in text box to the right)
---------------------------------------------------------------------------------------------
* * * Funding * * *
 
Please complete this section if:  1. This protocol will be funded, 2. You have submitted or will submit a grant
application associated with this protocol.  Please be sure to input your PASS/SP1 number to assist Sponsored
Programs in setting up an account for your funds.
If this protocol is funded by [CONTACT_152625], or will lead to the regulatory involvement of the FDA or EPA, please
be certain you are cognizant of any specific regulatory requirements for data acquisition, storage, retention and
sharing, as well as research expenditure allowability, with regard to this IRB protocol.
 
Funding Checklist
NONE
Â Â  Â Â  NOTE: Applicable Federal Grant Application, including competing renewals, must be attached in the
Attachment Section (#16). Applicable investigator's brochure and sponsor's protocol must also be
attached in section #16 for all industry-sponsored clinical trials.
 
Funding - Grants/Contracts
Funding - Fellowships
Funding - Other
 
Gift Funding
Dept. Funding
Other Funding
Other Fund Name [CONTACT_289661] #, if known [ZIP_CODE]
---------------------------------------------------------------------------------------------
Page 7 of 25
 * * * Expedited Paragraphs * * *
 
PLEASE READ:  This online application is for projects that will be reviewed by [CONTACT_152626]-
board review process.  The criteria for expedited review are listed below. Review and check what expedite
criteria is/are appropriate for your project. NOTE:  If your research involves or may involve greater than minimal
risk, an element of deception, or is FDA-regulated research, do NOT check any of the expedited criteria listed
below.  Your protocol will then be reviewed by [CONTACT_152627]-board at their next regularly scheduled meeting.  If your
project meets the exempt criteria, please submit your exempt application via email to:
[EMAIL_3134].  Information regarding exempt applications can be found here:
http://ricro.colostate.edu/IRB/ExemptReview.html
 
Â  Expedite Criteria:
 
1. Clinical studies of drugs and medical devices only when condition (a) or (b) is met.
 
a)Â  Research on drugs for which an investigational new drug application (21 CFR Part 31,32) is
not required. (Note: Research on marketed drugs that significantly increases the risks or
decreases the acceptability of the risks associated with the use of the product is not eligible
for expedited review.)
 
b)Â  Research on medical devices for whichÂ  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â 
Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â 
 
Â Â Â Â Â Â i)Â  An investigational device exemption application (21 CFR Part 812) is not required; or
Â Â Â Â Â Â ii)Â  The medical device is cleared/approved for marketing and the medical device is being used in
accordance with its cleared/approved labeling.
 
2. Collection of blood samples by [CONTACT_25877], heel stick, ear stick, or venipuncture as follows:
 
a)Â  From healthy, nonpregnant adults who weigh at least 110 pounds. For these subjects, the
amounts drawn may not exceed 550 ml in an 8- week period and collection may not occur
more frequently than 2 times per week; or
 
b)Â  From other adults and children, considering the age, weight, and health of the subjects, the
collection procedure, the amount of blood to be collected, and the frequency with which it will
be collected. For these subjects, the amount drawn may not exceed the lesser of 50 ml or 3
ml per kg in an 8-week period and collection may not occur more frequently than 2 times per
week.
 
3. Prospective collection of biological specimens for research purposes by [CONTACT_105]-invasive means.
 
4. Collection of data through non-invasive procedures (not involving general anesthesia or sedation)
routinely employed in clinical practice, excluding procedures involving x-rays or microwaves. Where
medical devices are employed, they must be cleared/approved for marketing. (Studies intended to
evaluate the safety and effectiveness of the medical device are not generally eligible for expedited
review, including studies of cleared medical devices for new indications.)
 
Examples:
a)Â  Physical sensors that are applied either to the surface of the body or at a distance and do not
involve input of significant amounts of energy into the subject or an invasion of the subject's
privacy;
b)Â  Weighing or testing sensory acuity; Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â 
Â  Â  Â  Â  Â  Â 
c)Â  Magnetic resonance imaging; Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â 
Â  Â  Â 
d)Â  Electrocardiography, electroencephalography, thermography, detection of naturally occurring
Page 8 of 25
 radioactivity, electroretinography, ultrasound, diagnostic infrared imaging, doppler blood flow,
and echocardiography;
e)Â  Moderate exercise, muscular strength testing, body composition assessment, and flexibility
testing where appropriate given the age, weight, and health of the individual.
 
5. Research involving materials (data, documents, records, or specimens) that have been collected, or
will be collected solely for nonresearch purposes (such as medical treatment or diagnosis). (NOTE:
Some research in this paragraph may be exempt from the HHS regulations for the protection of
human subjects. 45 CFR 46.101(b)(4). This listing refers only to research that is not exempt.)
 
6. Collection of data from voice, video, digital, or image recordings made for research purposes.
 
7. Research on individual or group characteristics or behavior(including, but not limited to, research on
perception, cognition, motivation, identity, language, communication, cultural beliefs or practices, and
social behavior) or research employing survey, interview, oral history, focus group, program
evaluation, human factors evaluation, or quality assurance methodologies. (NOTE: Some research in
this category may be exempt from the HHS regulations for the protection of human subjects. 45 CFR
46.101(b)(2) and (b)(3). This listing refers only to research that is not exempt.)
 
 
---------------------------------------------------------------------------------------------
* * * Purpose,Study Procedures,Background * * *
 
Original Protocol Number (e.g., 07-226H)
Â Â Â  Title (Please indicate if the protocol title is different from the proposal title)
Medical marijuana and its effects on motor function in people with Multiple Sclerosis: An observational
case-control study.
 
Â Â Â Â Â Â Complete Sections 1 - 16. Specify N/A as appropriate. Do not leave any required sections blank.
1. Purpose of the study
a) Provide a brief lay summary of the project in <200 words.  The lay summary should be readily
understandable to the general public, and is, for example, what would be released to a newspaper if
requested.
Medical marijuana is commonly prescribed people with Multiple Sclerosis (MS) for symptom, e.g. spasticity
and pain, management. Unfortunately not much is known about its effects outside the treatment for these [ADDRESS_353354] lower
levels of physical disability and improved walking abilities. A major limitation of these previous studies is
that the investigators used subjective measures of motor function. In this proposed observational case-
control study we plan to objectively measure multiple domains of motor function, such as: fatigue, strength,
and walking ability in people with MS who are smoking medical marijuana.. No marijuana will be brought
on to campus or given to participants. After an online screening and initial phone interview cases (medical
marijuana users (smokers)) and controls (non-users) will perform a battery of clinical testing over the
course of 3 sessions spread across a 3 week period. Participants will use a log to track their medical
marijuana use, which was identified as an area that needed more investigation during the NIHâ€™s
symposium on marijuana and cannabinoids held at the NIH campus 22 and 23 March, 2016.
 
b) What does the Investigator(s) hope to learn from the study?
We expect to identify alterations in motor performance between medical marijuana users (smokers) and
non-user who have MS. This line of inquiry will open up future research avenues into the long term
benefits and consequences of chronic medical marijuana usage for the treatment of physical impairments
in people with MS. We also hope to begin the formation of preliminary usage guidelines for people with MS
contemplating using medical marijuana for symptom management.
We hope to determine how regular cannabis use alters resting brain activity in people with MS.
 
Page 9 of 25
 c) Proposed Start Date (may not precede IRB approval date):
August 2016
 
2.Â 
Study Procedures (If this is a student project, the methods section of the thesis or dissertation proposal
must be attached in section #16 - Attachment section.)
 
a) In lay language, describe all the procedures, from screening through end-of-study, that the human subject
must undergo in the research project, including study visits, drug treatments, randomization and the
procedures that are part of standard of care.  Please note: Do NOT respond "See Attachment Section." If
you would like to add tables, charts, etc., attach those files in the Attachment section (#16).
Prospective participants will be recruited from the Integrative Neurophysiology Laboratoryâ€™s (INPL)
participant database, the clinical practice of [CONTACT_152673], Banner Health, Greeley CO, and through
advertisements in the Colorado and Wyoming Chapter of the National MS Society newsletters. All
experimental procedures will be performed in the INPL (Director: Thorsten Rudroff, PhD, FACSM).
Interested individuals will perform an initial screening via an online questionnaire, hosted by [CONTACT_38385],
which has a contract with the College of Health and Human Sciences. Contact [CONTACT_152628]â€™ information will be accessible only to the research staff according to HIPPA
regulations. After completion of the online screening form, INPL personal will contact [CONTACT_289658] 20 case/control matched pairs, [ADDRESS_353355] staff will schedule the participantsâ€™ first visit. Eligibility requirements for this study are:
medically diagnosed with MS, 30-75 years of age, Moderate disability (Patient Determined Disease Steps
score 2-6). Cases will verbally confirm their usage of medical marijuana before matching is conducted. We
will only recruit people with MS who smoke medical marijuana. Exclusion criteria include: relapse with the
last 60 days; high risk for cardiovascular disease (American College of Sports Medicine risk classification);
changes in disease modifying medications within the last 45 days; concurrent neurological/neuromuscular
disease, concurrent conditions unrelated to MS that would exacerbate fatigue (anemia, hypothyroidism,
shiftwork-related fatigue, B12 deficiency, major sleep disorder, or major depressive disorder); history of
traumatic brain injury, seizure disorders, hydrocephalus, traumatic brain injury; diabetes; hospi[INVESTIGATOR_289654] 90 days; alcohol dependence (>2 drinks per day); present history (last six months) of drug
abuse; and inability to understand/sign informed consent. Additional participants may be screened and
recruited if problems arise within a matched pair, e.g. participants drop out or are unable to meet time
commitments.
Medical Marijuana users will be asked to refrain from using cannabis for 8 hours prior to all testing and
training to prevent any behavioral/physiological effects of acute intoxication which result from THC.
The experimental protocol for this study consists of three testing sessions.
Session 1
Upon arrival to the Integrative Neurophysiology Lab (INPL) at CSU the investigators will explain the
protocol procedures and receive signed informed consent from the participants. After consent a urinalysis
assessment for Î”9-tetrahydrocannabinol (THC) will be performed to confirm case/control status. Next
participants will complete several questionnaires: Activities-specific Balance Confidence (ABC) Scale,
Fatigue Severity Scale (FSS), Beckâ€™s Depression Inventory (BDI), the MS Quality of Life (MSQOL)-54
Instrument, the MOS Pain Effects Scale (PES), and the Numeric Rating Scale of Spasticity (NRS). After
the questionnaires are complete the participants will undergo a resting metabolic rate (RMR) test. For the
RMR participants will be in a supi[INVESTIGATOR_73414] [ADDRESS_353356]. During this visit participants will
perform the MS Functional Composite (MSFC), which consists of a [ADDRESS_353357] (25FWT), the [ADDRESS_353358] (9HPT), and the Paced Auditory Serial Addition Test (PASAT). For the 25FWT participants will be
asked to walk [ADDRESS_353359] staff will walk alongside the participants to minimize the risk of falling. Next the 9HPT will be
performed. Participants will begin w/ their dominant hand and quickly move [ADDRESS_353360] moderator. (Previously performed in
IRB# 14-5152H)
After the MSFC is concluded participants will rest for at least [ADDRESS_353361] of sensory interaction on balance (mCTSIB).
For this test participants will be asked to stand with their feet together with no shoes on. They will stand
quietly in this position for 30 sec under 4 conditions: eyes open, eyes closed, eyes open on a foam pad,
and eyes closed on a foam pad. At the conclusion of balance testing participants will rest in a seated
position for at least [ADDRESS_353362] will be given/demonstrated.
After balance assessment strength testing of the right and left legs will be performed. Participants will
perform strength testing in a seated position with their knee and hip joints at 90 degrees of flexion. A linear
force transducer will be attached to the participantâ€™s ankle. Once the participant is in the proper position
they will be instructed to perform a series of isometric maximal voluntary contractions (MVC). Participants
will be instructed to increase the force of the knee extensors over a period of [ADDRESS_353363]. Once the participantsâ€™ MVC no longer increases in force the investigators will unstrap the personâ€™s leg
and test the other side. (Previously performed in IRB# 14-5152H)
The next procedure to be performed will be the [ADDRESS_353364] (6MWT). For this test participants will be
asked to walk as far as they can in [ADDRESS_353365] participants will be asked their rating of perceived exertion (RPE, 0-10
scale).
Session [ADDRESS_353366] visit for both the left and right quadriceps. Three MVC will
be performed to verify strength tested during visit 2. Participants will perform 2 trials at 3 different force
levels (5, 25, and 50% MVC), in a randomized order, holding each force level for [ADDRESS_353367] will be given between each trial. Tests will be performed on the right and left legs. Surface
electromyography will be performed on the muscles of the quadriceps femoris and hamstrings (vastus
lateralis, vastus medialis, rectus femoris, and biceps femoris). Visual feedback will be provided to the
participants on a computer monitor positioned at eye level approximately [ADDRESS_353368] performed will be the timed-up-and-go (TUG), which consists of rising from a chair, walking [ADDRESS_353369] approximately 2 hours
 
b) Explain why human subjects must be used for this project.
The goal of this project is to determine how medical marijuana affects aspects of motor performance in
people with MS. Therefore all clinical testing needs to be performed in the patient population that is being
studied.
 
c) Alternative Procedures. If the proposed study is a clinical trial of a drug, vaccine, device or treatment,
describe alternative procedures, if any, that might be advantageous to the subject. Describe the important
potential risks and benefits associated with the alternative procedure(s) or course(s) of treatment. Any
standard treatment that is being withheld must be disclosed. This information must be included in the
consent form.
N/A
 
Page 11 of 25
 d) If the proposed study is a clinical trial of a drug, vaccine, device or treatment, will it be possible to continue
the more (most) appropriate therapy for the subject(s) after the conclusion of the study?
N/A
 
e) Study Endpoint. If the proposed study is a clinical trial of a drug, vaccine, device or treatment, what are the
guidelines or end points by [CONTACT_152630]? If one
treatment proves to be clearly more effective than another (or others) will the study be terminated before
the projected total subject population has been enrolled? When will the study end if no important
differences are detected?
N/A
 
f) State if deception will be used. If so, provide a rationale and describe debriefing procedures. Submit a
debriefing script in the Attachment Section (#16).
N/A
 
3. Background
a) Describe past experimental and/or clinical findings leading to the formulation of the study, if applicable.
Several participants in our previous study investigating the predictors of physical activity in patients with
MS were using cannabis products. When these individuals were compared to matched individuals they
seemed to perform better on the tests measuring motor function. From this initial data, only 4 cannabis
users, we became interested in determining if medical marijuana would improve physical function and
fatigue in people with MS. Currently we are performing an anonymous online survey hosted through the
Qualtrics website investigating cannabis use in people with neurological disorders (CSU IRB# 126-16H ).
To date, over [ADDRESS_353370] taken this survey, with approximately 40% stating they currently use
cannabis based products for symptom management.
 
b) Describe any animal experimentation and findings leading to the formulation of the study, if applicable.
---------------------------------------------------------------------------------------------
* * * Radioisotopes or Radiation Machines * * *
 
 
You selected NO for Radioisotopes in the General Checklist. If you would like to add Radioisotopes, change the
selection to YES in general Checklist.
 
4.Â 
Radioisotopes or Radiation Machines Please note: For projects requiring radiation procedures, please
contact [CONTACT_152631] (RCO). For more information see:
http://www.ehs.colostate.edu/WRad/Home.aspx :
 
Â  a)Â  If applicable, summarize in lay language the radiographic diagnostic and therapeutic procedures
associated with this protocol.
N/A
Â Â b)Â 
Are the radiation procedures being performed a normal part of the clinical management for the medical
condition that is under study (Standard of Care) or are the procedures being performed because the
research subject is participating in this project (extra CT scans, more fluoroscopy time, additional Nuclear
Medicine Studies, etc.,) (Not Standard of Care)? If some procedures are Standard of Care and some are
Not Standard of Care, check both boxes.
 
Â Â  NOT STANDARD OF CARE STANDARD OF CARE
Â Â  If it is not standard of care, complete the rest of
this section. Provide the CSU RCO approvalIf it is only standard of care, skip the rest of this
section.
Page 12 of 25
 this section. Provide the CSU RCO approval
informationsection.
 
Â  CSU Radiation Control Office approved protocol number:
 
Â  CSU Radiation Control Office protocol approval date:
Â 
For more information, see the RCO website at:<a href='http://www.ehs.colostate.edu/Wrad/home.aspx'
target=_blank >http://www.ehs.colostate.edu/Wrad/home.aspx or Contact: [CONTACT_152632], Radiation
Safety Officer, at [PHONE_3427].
---------------------------------------------------------------------------------------------
* * * Medical Equipment for Human Subjects and Laboratory Animals; Investigatiional Devices * * *
 
 
5. Medical Equipment for Human Subjects
 
Â Â  If medical equipment is being used for human subjects/patients, describe this equipment and indicate if the
use is normal practice for the population under study. You may have already described this equipment in
the Study Procedures section. If you have already listed this information in the Study Procedures Section,
please do not duplicate this information here. In the space below, input N/A if not applicable, indicate if this
is already listed in the Study Procedures Section, or describe the equipment.
N/A
 
 
6. Investigational Devices
Â Â Â Â Â Â Â Â Â Please list in the space below all Investigational Devices to be used on Subjects.
Investigational Devices
---------------------------------------------------------------------------------------------
* * * Drugs, Reagents, or Chemicals * * *
 
 
7. Drugs, Reagents, or Chemicals
Â a) Please list in the space below all investigational drugs, reagents or chemicals to be administered to
subjects during this study.
 
Â b) Please list in the space below all commercial drugs, reagents or chemicals to be administered to subjects
during this study.
 
 
Please read the IND Statements
---------------------------------------------------------------------------------------------
* * * Subject Population (a-g) * * *
 
 
8. Â 
Page [ADDRESS_353371] Population - In the space below, please detail the participants that you are requesting to recruit
(include requested participant number and description of each group requested).  (Input N/A if not
applicable)
a) Requested Participant Description (Include number of participants that you plan to study and description of
each group requested, if applicable).
We plan on recruiting 40 people with MS:  20 are regular cannabis users (smokers), 20 are not users, with
an estimate that approximately 5 from each group will not complete the study (i.e. drop out).
 
b) What is the rationale for studying the requested group(s) of participants?
To investigate the effects of medical marijuana usage on physical function we will employ an observational
case-control design. Cases (MS medical marijuana users) will be compared to age, sex, and disease
duration matched controls (MS non-cannabis users). The research team has experience with all the
methods involved.
 
c) If applicable, state the rationale for involvement of potentially vulnerable subjects to be entered into the
study, including minors, pregnant women, economically and educationally disadvantaged, or decisionally
impaired subjects. Specify the measures being taken to minimize the risks and the chance of harm to the
potentially vulnerable subjects.
N/A
 
d) If women, minorities, or minors are not included, a clear compelling rationale must be provided. Examples
for not including minors: disease does not occur in children; drug or device would interfere with normal
growth and development; etc.
N/A
 
e) State if any of the subjects are students, employees, or laboratory personnel. They should be presented
with the same written informed consent. If compensation is allowed, they should also receive it.
N/A
 
f)Â  Describe how potential subjects will be identified for recruitment (e.g., chart review, referral from individual's
treating physician, those individuals answering an ad). How will potential participants learn about the
research and how will they be recruited (e.g., flyer, email, web posting, telephone, etc.)? Attach recruitment
materials in the Attachment Section (#16). Important to remember: potential subjects may not be contact[CONTACT_152633].
Prospective participants will be recruited from the Integrative Neurophysiology Laboratoryâ€™s (INPL)
participant database, the clinical practice of [CONTACT_152673], Banner Health, Greeley CO, and through
advertisements in the Colorado and Wyoming Chapter of the National MS Society newsletters. All
experimental procedures will be performed in the INPL (Director: Thorsten Rudroff, PhD, FACSM).
Interested individuals will perform an initial screening via an online questionnaire, hosted by [CONTACT_38385],
which has a contract with the College of Health and Human Sciences. Contact [CONTACT_152628]â€™ information will be accessible only to the research staff according to HIPPA
regulations. After completion of the online screening form, INPL personal will contact [CONTACT_289658] 20 case/control matched pairs, [ADDRESS_353372] staff will schedule the participantsâ€™ first visit.
 
g)Â  If applicable, provide rationale for the inclusion of healthy volunteers in this study. Specify any risks to
which these healthy volunteers may possibly be exposed. Specify the measures being taken to minimize
the risks and the chance of harm to these volunteers.
N/A
---------------------------------------------------------------------------------------------
* * * Subject Population (h-m) * * *
 
 
8. Subject Population (Input N/A if not applicable)
Page 14 of 25
 h) Inclusion and Exclusion Criteria (e.g., Participants must have 20/[ADDRESS_353373] be 30-45
years of age, etc.)
 
Â  Â Â  Â Â Â  Identify inclusion criteria.
Medically diagnosed with MS, 30-60 years of age, Moderate disability (Patient Determined
Disease Steps score 2-6). Cases will verbally confirm their usage of medical marijuana
(smokers) before matching is conducted.
 
Â  Â Â  Â Â Â  Identify exclusion criteria.
Relapse with the last 60 days, high risk for cardiovascular disease (American College of Sports
Medicine risk classification), changes in disease modifying medications within the last 45 days,
concurrent neurological/neuromuscular disease, hospi[INVESTIGATOR_854] 90 days, and
inability to understand/sign informed consent. Additional participants may be screened and
recruited if problems arise within a matched pair, e.g. participants drop out or are unable to
meet time commitments.
â€¢A condition unrelated to MS that would exacerbate fatigue, such as anemia, hypothyroidism,
shiftwork-related fatigue, B12 deficiency, major sleep disorder, or major depressive disorder
â€¢Medical diagnosis or condition that  makes participating in exercise training dangerous, such
as major renal, pulmonary, hepatic, cardiac, gastrointestinal, HIV, cancer (other than treated
basal cell cancer), other neurological disorders, or pregnancy
â€¢History of heart attack or current diagnosis of cardiovascular disease
â€¢History of seizure disorders (or on medications known to lower seizure threshold),
hydrocephalus (buildup of fluid in the brain), or diabetes
â€¢Alcohol dependence or abuse (>2 drinks/day), or present history (last six months) of drug
abuse
â€¢History of significant traumatic brain injury or hydrocephalus
â€¢Pregnancy
â€¢Recent hospi[INVESTIGATOR_059] (within the last 3 months) or enforced bed
   rest/sedentary state.
 
i) Describe your screening procedures. Attach your screening document(s) (e.g., health history
questionnaire) in the Attachment Section (#16).
Prospective participants will be recruited from the Integrative Neurophysiology Laboratoryâ€™s (INPL)
participant database, the clinical practice of [CONTACT_152673], Banner Health, Greeley CO, and through
advertisements in the Colorado and Wyoming Chapter of the National MS Society newsletters. All
experimental procedures will be performed in the INPL (Director: Thorsten Rudroff, PhD, FACSM).
Interested individuals will perform an initial screening via an online questionnaire, hosted by [CONTACT_38385],
which has a contract with the College of Health and Human Sciences. Contact [CONTACT_152628]â€™ information will be accessible only to the research staff according to HIPPA
regulations. After completion of the online screening form, INPL personal will contact [CONTACT_289658] 20 case/control matched pairs, [ADDRESS_353374] staff will schedule the participantsâ€™ first visit.
 
j) Describe how you will be cognizant of other protocols in which subjects might be participating. Please
explain if subjects will be participating in more than one study.
We will ask participants whether they are involved in other studies. If they are, we make sure that there are
no interference.
 
k) Compensation. Explain the amount and schedule of compensation, if any, that will be paid for participation
in the study. Compensation includes food, gift cards, money, tokens, etc. Include provisions for prorating
payment, if applicable.  Compensation should be prorated if several activities are involved for different time
periods (e.g., $10 for session #1, and $10 for session #2).
Participants will receive compensation for their time in the lab totaling $75.00. Participants will receive a
$20, $25, and $[ADDRESS_353375] session respectively.
 
l) Costs. Please explain any costs that will be charged to the subject.
No costs for participants.
Page 15 of 25
  
m) Estimate the probable duration of the entire study. This estimate should include the total time each subject
is to be involved and the duration the data about the subject is to be collected (e.g., This is a 2-year study.
Participants will be interviewed 3 times per year; each interview will last approximately 2 hours.  Total
approximate time commitment for participants is 12 hours).  These times should be consistent with the time
commitment listed on the consent document.
The probable duration of the study will be 12 months.
1. Visit: 2-3 hours
2. Visit 2-3 hours
3. Visit 2 hours
---------------------------------------------------------------------------------------------
* * * Risks * * *
 
 
9. Risks (Input N/A if not applicable)
Â Â Â Â Â 
US Department of Health & Human Services (HHS) Regulations define a subject at risk as follows: "...any
individual who may be exposed to the possibility of injury, including physical, psychological, or social injury,
as a consequence of participation as a subject in any research, development, or related activity which
departs from the application of those accepted methods necessary to meet his needs, or which increases
the ordinary risks of daily life, including the recognized risks inherent in a chosen occupation or field of
service."
 
Â a)Â  PI's evaluation of the overall level of Risk. (Please check one: minimal or > minimal.)
Y Minimal (everyday living)
> Minimal (greater than everyday living)
 
Â b)Â Â Â 
For the following categories include a scientific estimate of the frequency, severity, and reversibility of
potential risks. Wherever possible, include statistical incidence of complications and the mortality rate of
proposed procedures. Where there has been insufficient time to accumulate significant data ON risk, a
statement to this effect should be included. (In describing these risks in the consent form to the subject, it is
helpful to use comparisons which are meaningful to persons unfamiliar with medical terminology.) Address
any risks related to:
 
 
Â Â Â  Â Â Â  1.Â Â Â  Use of investigational devices. Please include the clinical adverse events (AEs) associated with
each of the devices with an indication of frequency, severity and reversibility. This information
can often be found in the Investigator(s) brochure.
N/A
 
 
Â Â Â  Â Â Â  2Â Â Â  Use of investigational drugs. Please include the clinical AEs associated with each of the drugs
with an indication of frequency, severity and reversibility. This information can often be found in
the Investigator(s) brochure.
N/A
 
 
Â Â Â  Â Â Â  3Â Â Â  Use of commercially available drugs, reagents or chemicals. Please include the clinical AEs
associated with each of the drugs with an indication of frequency, severity and reversibility. This
information can often be found in the package insert provided by [CONTACT_3455].
N/A
Page 16 of 25
  
 
Â Â Â  Â Â Â  4Â Â Â  When performing procedures, please include all investigational, non-investigational and non-
invasive procedures (e.g., surgery, blood draws, treadmill tests).
Motor Tasks
The most likely adverse event to happen during this protocol is a fall. During the performance of
all tests research personnel will be within an arms distance of the participants to provide
support if needed. The hallway in which the [ADDRESS_353376] Human Performance and Clinical Research Laboratory procedures.
Minor muscle pain/stiffness/cramps can occur during the performance of the different strength
measurements. If this occurs, the participant will be allowed to move/stretch/massage the
muscle. If pain is increased or participant is uncomfortable completing the strength testing
those assessments will be skipped. Minor skin irritation can also occur from the surface
electromyography electrodes. After and area is properly prepped, if the participant has a skin
reaction the electrodes will not be utilized and the task will be performed sans
electromyography.
 
 
Â Â Â  Â Â Â  5Â Â  Radioisotopes/radiation-producing machines(e.g., X-rays, CT scans, fluoroscopy).
N/A
 
 
c)Â Â Â Â Â Â 
For the following categories, include an estimate of the potential risk, if applicable.
 
 
Â Â Â  Â Â Â  1.Â Â Â  Physical well-being.
Motor tasks
The most likely adverse event to happen during this protocol is a fall. During the performance of
all tests research personnel will be within an arms distance of the participants to provide
support if needed. The hallway in which the [ADDRESS_353377] Human Performance and Clinical Research Laboratory procedures.
Minor muscle pain/stiffness/cramps can occur during the performance of the different strength
measurements. If this occurs, the participant will be allowed to move/stretch/massage the
muscle. If pain is increased or participant is uncomfortable completing the strength testing
those assessments will be skipped. Minor skin irritation can also occur from the surface
electromyography electrodes. After and area is properly prepped, if the participant has a skin
reaction the electrodes will not be utilized and the task will be performed sans
electromyography.
 
 
Â Â Â  Â Â Â  2.Â Â Â  Psychological well-being.
N/A
 
 
Â Â Â  Â Â Â  3.Â Â Â  Economic well-being.
N/A
Page 17 of 25
  
 
Â Â Â  Â Â Â  4.Â Â Â  Social well-being.
N/A
 
Â d)Â  In case of overseas research, or working with a specific race/ethnicity in the [LOCATION_002], provide
background on what experience the Investigator(s) have with the proposed population. Describe
qualifications/preparations that enable the Investigator(s) to evaluate cultural appropriateness and
estimate/minimize risks to subjects.
N/A
 
Â e)Â  Special Precautions. Describe the planned procedures for protecting against or minimizing potential risks. If
appropriate, include the standards for termination of the participation of the individual subject. Discuss
plans for ensuring necessary medical or professional intervention in the event of adverse effects to the
subjects.
N/A
 
Â f)Â 
Data Safety MonitoringÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 
Â Â Â Â  N Is there a Data Safety Monitoring Board (DSMB)?
 
 
Â Â Â  Â Â Â  Â Â Â  If yes, describe its role and indicate who set up the Data Safety Monitoring Board (e.g., sponsor
or Protocol Director).
 
 
Â Â Â  Â Â Â  Â Â Â  Describe the data and safety monitoring plan developed to ensure the safety of participants and
the validity and integrity of research data. Monitoring should be commensurate with risks and
with the size and complexity of the trials.
---------------------------------------------------------------------------------------------
* * * Benefits, Procedures to Maintain Confidentiality * * *
 
 
10. Benefits (Input N/A if not applicable)
a) Describe the potential benefit(s) to be gained by [CONTACT_748]. If there is no direct benefit to the subjects
describe how the results of the study may benefit society or a particular group.
There is no direct benefit from participating in this research study to the individual research participants.
The knowledge derived from this study will allow people with Multiple Sclerosis the ability to make a more
informed decision regarding medical marijuana use for disease symptom management. Currently there are
no scientifically based guidelines for the use of medical marijuana for this population. This research
protocol will provide the groundwork to establish these guidelines allowing medical practitioners and
patients to make informed decisions about the possible benefits and consequences of medical marijuana
use.
 
11. Procedures to Maintain Confidentiality
a) Describe the procedures that protect the privacy of the subjects and maintain the confidentiality of the data.
If a linked list is used, explain when the linked list will be destroyed.  Provide a sample of the code that will
be used, if applicable.
Personal identification is limited to the initial online screening. After eligibility has been determined,
Page 18 of 25
 prospective participants will be assigned a unique study ID, example: MSMMJ-###. Subsequent to the
assignment of the study ID, all data collected will be collected under the individualâ€™s study ID only. A list
corresponding personal data to study ID will be kept in a locked filing cabinet within theINPL where access
is restricted to authorized key holders. All data will be kept for a minimum of 3 years according to
University / State / Federal regulations. All hard copy data will be destroyed via burning at the time that
study data is no longer needed/required.
 
b) If information derived from the study will be provided to the subject's personal physician, a government
agency, or any other person or group (other than the research team), describe to whom the information will
be given and the nature of the information, if applicable.
N/A
 
c) Specify where and under what conditions study data will be kept, how samples will be labeled, who has
access to the data, and what will be available and to whom.  Federal regulations require that study data
and consent documents be kept for a minimum of three (3) years after the completion of the study by [CONTACT_51336].  For longitudinal projects and federally regulated studies, the PI [INVESTIGATOR_152613] a longer time period.
Electronic data will be stored on the university computer network with access restricted to research
personnel. Computers are password protected and require direct on-campus to connections for access.
Hard copy information will be stored in a locked filing cabinet in the Integrative Neurophysiology
Laboratory. Access to the room is restricted to authorized key holders (Director: Thorsten Rudroff,
Students: John Kindred, Nathan Ketelhut). Afterhours access to the building and the department space is
restricted to authorized personnel (Department faculty and staff) between the hours of 1700-0700. All data
will be kept on hand for at least [ADDRESS_353378] copi[INVESTIGATOR_289655]â€™s computer system via system administrators. Any backups containing data will
be cleaned and sanitized using University approved procedures by [CONTACT_289659].
Urine samples will be collected for confirmation of participantâ€™s group status (case versus control). After
immediate confirmation with testing strips the biological samples will be disposed in approved biological
sample containers per University / State / Federal regulations.
---------------------------------------------------------------------------------------------
* * * Potential Conflict of Interest * * *
 
 
12. Potential Conflict of Interest
Although you have already submitted CSU's official Conflict of Interest form (FCOI/COI/COC) to the
University, it is the IRB's responsibility to ensure that conflicting interests related to submitted protocols do
not adversely affect the protection of participants or the credibility of the human research protection program
at CSU. Please answer questions a-d below.  Please note that if you indicate that you have a potential
financial or professional conflict of interest in relation to this protocol, your CSU FCOI/COI/COC Reporting
Form must reflect this potential conflict.  Link to CSU's Conflict of Interest policy:
:http://www.facultycouncil.colostate.edu/files/manual/sectiond.htm#D.7.7
a) N In connection with this protocol, do you or any of the protocol investigators or their
immediate family members (i.e., spouse and legal dependents, as determined by [CONTACT_152637])
have a potential financial or professional conflict of interest?
b) N/A If you do have a potential conflict of interest, is this reported in your current
FCOI/COI/COC?
c) N/A If you do have a potential conflict of interest, is there a management plan in place to
manage this potential conflict?
d) N/A If you do have a potential conflict of interest, is this potential conflict of interest included in
your consent document (as required in the Management Plan)?
 
If you have reported a possible conflict of interest, the IRB will forward the title of this protocol to your Research
Associate Dean to complete your COI file. 
 
Page 19 of 25
 For more information on CSU's policy on Conflict of Interest, please see the Colorado State University
Academic Faculty and Administrative Professional Manual Sections D.7.6 & D.7.7.
:http://www.facultycouncil.colostate.edu/files/manual/sectiond.htm#D.7.7
 
Link to CSU's Conflict of Interest Policy: http://www.provost.colostate.edu/index.asp?url=faculty_affairs.
---------------------------------------------------------------------------------------------
* * * Informed Consent * * *
 
 
13. Informed Consent
NOTE: In order to complete this protocol, you must upload either a Consent Form or an Alteration of
Consent Form (i.e., Cover Letter or Verbal Script) OR (if neither of those apply to your project) you must
complete the Waiver of Consent information.
In the space below, please provide consent process background information for each Consent Form(s),
Alteration of Consent Form(s), or Waiver(s).
Informed Consent
Â Â Title Control Consent Am 4 12May2017
Â Â Consent Information Type Consent
Â Â Sponsor's Consent Version Number: (if any)
Consent Form Template X Attachment Â  Consent_Control_Group_2017051
2 (2)
<a href='http://ricro.colostate.edu/IRB/ConsentAssentTemplates.html' target=_blank Consent Form
Samples
Who is obtaining consent? The person obtaining consent must be knowledgeable about the study and
authorized by [CONTACT_978] [INVESTIGATOR_152614].
How is consent being obtained?
What steps are you taking to determine that potential subjects are competent to participate in the decision-
making process?
Â Â Title MMJ Consent Am 4 12May2017
Â Â Consent Information Type Consent
Â Â Sponsor's Consent Version Number: (if any)
Consent Form Template X Attachment Â  Consent_MMJ_Group_20170512
(1)
<a href='http://ricro.colostate.edu/IRB/ConsentAssentTemplates.html' target=_blank Consent Form
Samples
Who is obtaining consent? The person obtaining consent must be knowledgeable about the study and
authorized by [CONTACT_978] [INVESTIGATOR_152614].
How is consent being obtained?
What steps are you taking to determine that potential subjects are competent to participate in the decision-
making process?
---------------------------------------------------------------------------------------------
Page 20 of 25
 * * * Assent Background * * *
 
 
14. Assent Background  (Complete if applicable)
All minors must provide an affirmative consent to participate by [CONTACT_2960] a simplified assent form, unless the
Investigator(s) provides evidence to the IRB that the minor subjects are not capable of assenting because of
age, maturity, psychological state, or other factors.
See sample consent/assent forms at <a href=http://ricro.colostate.edu/IRB/ConsentAssentTemplates.html
target=_blank > http://ricro.colostate.edu/IRB/ConsentAssentTemplates.html
Provide assent process background information, in the space below, for each Assent Form, Alteration Form
(i.e., Cover Letter or Verbal Script), and Waiver.
Assent  Background
---------------------------------------------------------------------------------------------
Page 21 of 25
 * * * HIPAA * * *
 
 
15. HIPAA
Are you using PHI*? (See definition below)
Y
Colorado State University is a hybrid entity and does not have a research-related HIPAA policy. If you will be
working with a HIPAA covered entity (e.g., Poudre Valley Health System), you will need to follow their HIPAA
guidelines. If your project will involve a HIPAA-regulated entity, in the Attachment section (#16) please attach that
entity's required HIPAA consent and/or each waiver of authorization or alteration of authorization requested (e.g.,
waiver of authorization for access to medical records). Include HIPAA authorization language in the consent
document(s) as appropriate (e.g., when enrolling subjects).  
*Protected Health Information (PHI) is health information with one or more of the following identifiers. For
more information see: http://www.hhs.gov/ocr/hipaa/
Â Â 1. Names
Â Â 2. Social Security numbers
Â Â 3. Telephone numbers
Â Â 4. All geographic subdivisions smaller than a State, including street address, city, county, precinct,
zip code, and their equivalent geocodes, except for the initial three digits of a zip code, if,
according to the current publicly available data from the Bureau of the Census: (1) The
geographic unit formed by [CONTACT_152638] 20,000 people; and (2) The initial three digits of a zip code for all such geographic
units containing 20,000 or fewer people is changed to 000
Â Â 5. All elements of dates (except year) for dates directly related to an individual, including birth date,
admission date, discharge date, date of death; and all ages over 89 and all elements of dates
(including year) indicative of such age, except that such ages and elements may be aggregated
into a single category of age [ADDRESS_353379] numbers
Â Â 9. Health plan beneficiary numbers
10. Account numbers
11. Certificate/license numbers
12. Vehicle identifiers and serial numbers, including license plate numbers
13. Device identifiers and serial numbers
14. Web Universal Resource Locations (URLs)
15. Internet Protocol (IP) address numbers
16. Biometric identifiers, including finger and voice prints
17. Full face photographic images and any comparable images; and
18. Any other unique identifying number, character, or code (note this does not mean the unique
code assigned by [CONTACT_737](s) to code the research data)
---------------------------------------------------------------------------------------------
* * * Attachments * * *
 
16. Attachments
Attach relevant documents here. These could include: Collaborating Investigator's IRB approval and
approved documents; Conflict of Interest information; Debriefing Script; Grant/Sub-contract; HIPAA
Authorization Form from HIPAA-covered entity; Interview/Focus Group Questions; Investigator's Brochure;
Letters of Agreement/Cooperation from organizations who will help with recruitment; Methodology section of
associated Thesis or Dissertation project; Questionnaires; Radiation Control Office approval material;
Recruitment Material (e.g., flyers, email text, verbal scripts); Sponsor's Protocol; Surveys; Other files
associated with the protocol (you can upload most standard file formats: xls, pdf, jpg, tif, etc.)  Please be
sure to attach all documents associated with your protocol. Failure to attach the files associated with the
Page 22 of 25
 protocol may result in this protocol being returned to you for completion prior to being reviewed. Students:
Be sure to attach the Methods section of your thesis or dissertation proposal. If this protocol is associated
with a grant proposal, please remember to attach your grant.
To update or revise any attachments, please delete the existing attachment and upload the revised document to
replace it. 
Document Type Recruitment Material (e.g., flyers, email text, verbal
scripts)
Attachment Recruitment_flyer
Document Name [CONTACT_152662]_flyer
Document Type Other Protocol Material
Attachment MSQOL54_995
Document Name [CONTACT_289662]54_995
Document Type Other Protocol Material
Attachment MSFC_Manual_and_Forms
Document Name [CONTACT_289663]_Manual_and_Forms
Document Type Other Protocol Material
Attachment MMJ_use_log
Document Name [CONTACT_289664]_use_log
Document Type Other Protocol Material
Attachment FSS
Document Name [CONTACT_289665]_Depression_Inventory
Document Name [CONTACT_152654]_Depression_Inventory
Document Type Other Protocol Material
Attachment Activity LOG
Document Name [CONTACT_289666]_specific_balance_scale_nov_5_2012
Document Name [CONTACT_289667]_specific_balance_scale_nov_5_2012
Document Type Recruitment Material (e.g., flyers, email text, verbal
scripts)
Attachment Online_screening
Document Name [CONTACT_289668]_screening
Page [ADDRESS_353380]. Shaffer
Document Type HIPAA Authorization Form
Attachment HIPAA Release generic
Document Name [CONTACT_289669] (PES)
Document Name [CONTACT_289670] (PES)
Document Type Other Protocol Material
Attachment NRS_Spasticity_Figure [ADDRESS_353381] 2016 Report Public Final
Document Type Recruitment Material (e.g., flyers, email text, verbal
scripts)
Attachment Rudroff_Recruitment_flyer_MMJ (2) Qaualtric web
address
Document Name [CONTACT_289671]_Recruitment_flyer_MMJ (2) Qaualtric web
address
Document Type Other Protocol Material
Attachment Rehab Measures - Modified Clinical Test of Sensory
Interaction...[3726]
Document Name [CONTACT_289672] - Modified Clinical Test of Sensory
Interaction...[3726]
Document Type Collaborating Investigator's IRB approval and
associated documents
Attachment Rudroff NTF 16.6685HH
Document Name [CONTACT_289673] 16.6685HH
---------------------------------------------------------------------------------------------
Page 24 of 25
 * * * Obligations * * *
 
 
Obligations (Researcher's Responsibilities)
 
The Principal Investigator [INVESTIGATOR_152615]. Obligations of the Principal
Investigator [CONTACT_95003]:
 
Conduct the research involving human subjects as presented in the protocol, including modifications, as
approved by [CONTACT_152639]. Changes in any aspect of the study (for example
project design, procedures, consent forms, advertising materials, additional key personnel or subject populations)
will be submitted to the IRB for approval before instituting the changes (PI [INVESTIGATOR_152616] "Amendment/Revision"
form);
 
Provide all subjects a copy of the signed consent form, if applicable. Investigators will be required to retain signed
consent documents for three (3) years after close of the study;
 
Maintain an approved status for Human Subjects Protection training. Training must be updated every three (3)
years (Contact [CONTACT_152640]/renewal dates). For more information:  Human Subjects
Training Completed?
 
Submit either the "Protocol Deviation Form" or the "Report Form" to report protocol Deviations/Violations,
Unanticipated Problems (UPs) and/or Adverse Events (AEs) that occur in the course of the protocol. Any of these
events must be reported to the IRB as soon as possible, but not later than five (5) working days.  Note that if an
event resulted in life threatening injury or death OR an event resulted in substantive harm to the safety, rights or
welfare to human subjects, this must be reported to the IRB within 24 hours;
 
Submit the "Continuing Review" Form in order to maintain active status of the approved protocol. This form must
be submitted annually at least four (4) weeks prior to expi[INVESTIGATOR_1516], five (5) weeks for protocols that require full
review. If the protocol is not renewed before expi[INVESTIGATOR_1516], all activities must cease until the protocol has been re-
reviewed;
 
Notify the IRB that the study is complete by [CONTACT_152641] "Final Report" form.
 
Â Â  Â Â 
X The Principal Investigator [INVESTIGATOR_120810].
---------------------------------------------------------------------------------------------
* * * Event History * * *
Event History
Date Status View Attachments Letters
05/26/2016 NEW FORM CREATED
06/28/2016 NEW FORM SUBMITTED Y
07/05/2016 NEW FORM PANEL
ASSIGNED
07/14/2016 NEW FORM REVIEWER(S)
ASSIGNED
07/18/2016 NEW FORM REVIEWER(S)
ASSIGNED
Page 25 of 25
 08/01/2016 NEW FORM REVIEWER(S)
ASSIGNED
08/17/2016 NEW FORM MOVED
08/17/2016 NEW FORM APPROVED Y Y
10/03/2016 AMENDMENT 1 FORM
CREATED
10/04/2016 AMENDMENT 1 FORM
SUBMITTEDY
10/14/2016 AMENDMENT 1 FORM
REVIEWER(S) ASSIGNED
11/04/2016 AMENDMENT 1 FORM
REVIEWER(S) ASSIGNED
11/11/2016 AMENDMENT 1 FORM
MOVED
11/11/2016 AMENDMENT 1 FORM
APPROVEDY Y
11/11/2016 AMENDMENT 2 FORM
CREATED
11/11/2016 AMENDMENT 2 FORM
SUBMITTEDY
11/11/2016 AMENDMENT 2 FORM
APPROVEDY Y
02/22/2017 AMENDMENT 3 FORM
CREATED
02/22/2017 AMENDMENT 3 FORM
SUBMITTEDY
02/23/2017 AMENDMENT 3 FORM
REVIEWER(S) ASSIGNED
03/07/2017 AMENDMENT 3 FORM
APPROVEDY Y
05/12/2017 AMENDMENT 4 FORM
CREATED
05/15/2017 AMENDMENT 4 FORM
SUBMITTEDY
05/16/2017 AMENDMENT 4 FORM
REVIEWER(S) ASSIGNED
05/18/2017 AMENDMENT 4 FORM
MOVED
05/18/2017 AMENDMENT 4 FORM
APPROVEDY Y
06/06/2017 CONTINUING REVIEW 1
FORM CREATED
06/06/2017 CONTINUING REVIEW 1
FORM SUBMITTEDY
06/09/2017 CONTINUING REVIEW 1
FORM REVIEWER(S)
ASSIGNED
06/19/2017 CONTINUING REVIEW 1
FORM APPROVEDY Y
05/30/2018 FINAL FORM CREATED
05/30/2018 FINAL FORM SUBMITTED Y
05/30/2018 FINAL FORM APPROVED Y N
05/30/2018 CLOSED
    
 
Page 1 of 6 Participantâ€™s initials _______ Date _______   
Version 12May2017 
 
 CSU#: 16 -6685HH 
APPROVED:  6/15/2017 * EXPI[INVESTIGATOR_152617]: 6/14/2018  Consent to Participate in a Research Study  
Colorado State University  
 
TITLE OF STUDY: Medical marijuana and its effects on motor function in people 
with Multiple Sclerosis: An observational case- control study.  
 
 PRINCIPAL INVESTIGAT ORS:   
The principal investigator  [CONTACT_832] a researcher  in the Department of Health and Exercise 
Science at Colorado State University : 
 
Thorsten Rudroff, Ph.D. , FACSM       
[EMAIL_5670]
     
[PHONE_3428]         
 
WHY AM I BEING INVITED TO TAKE PART IN THIS RESEARCH?  
You are an adult aged between 30 and 60 years  of age, and you were diagnosed with 
Multiple Sclerosis.  
 WHO IS DOING THE STUDY?  
Dr. R udroff and the Integrative Neurophysiology Laboratory students/research staff . 
 
WHAT IS THE PURPOSE OF THIS STUDY?  
The purpose of this study is to determine possible benefits and consequences 
associated with medical marijuana use for the management of symptoms related to a 
diagnosis of Multiple Sclerosis .  
 
WHERE IS THE STUDY GOING TO TAKE PLACE AND HOW LONG WILL IT LAST?  
The study will take place in the Integrative Neurophysiology Laboratory  in the 
Department of Health and Exercise Science, on the Colorado State University  campus . 
The study will run for approximately 12 months. You will take part in the study for 
approximately  a total of 8 hours  over the spa n of three week s. 
 
WHAT WILL I BE ASKED TO DO?   
You will be asked to participate i n two sessions on two different days:  
 
Visit [ADDRESS_353382] visit will include the following procedures and tests:  
- Urinalysis : We will ask you to provide a urine sample for the confirmation of your 
research group assignment.  
- Questionnaires:  You will be asked to  complete a series of questionnaires to 
determine your fatigue levels, perceived risk  of fall ing, mood, and quality of life.   
- Resting Metabolic Rate: You will lay comfortably on a bed while we capture the 
air you are breathing out. Will analysis this air to determine how many calories 
    
 
Page 2 of 6 Participantâ€™s initials _______ Date _______   
Version 12May2017 
 
 CSU#: 16 -6685HH 
APPROVED:  6/15/2017 * EXPI[INVESTIGATOR_152617]: 6/14/2018  you typi[INVESTIGATOR_289656], proteins, or fats are 
your primary sources for energy generation.  
- Handgrip Strength:  We will measure your maximal handgrip strength using a 
device which you have to squeeze alternately with your left and right hand up to 
five times.  
- Physical Activity:  At the end of the first session, you will be introduced to the 
ActiGraph device, which will measure physical activity.  You will be asked to wear this device on your waist  for a period of seven days (five week days and two 
weekend days). You can remove the ActiGraph at night.  You will be asked to 
return the ActiGraph at your second experimental session, which will be at least seven days after the first session.   Furthermore, you will receive a log to track 
their wear time.   
 
This visit will last approximately 120- [ADDRESS_353383] of the following tests : 
- MS Functional Composite : This is a series of [ADDRESS_353384] you add (+) a series of numbers spoken on a computer.  
- Balance test:  In this test you will stand on a platform with your feet next to each 
other. You will stand quietly for 30 seconds in 4 different conditions: eyes open, eyes closed, eyes open on a foam pad, and eyes closed on a foam pad.  
- Leg Strength:  The maximal strength of each leg will be measured by [CONTACT_152643] a series of maximal effort knee extension, knee flexion, plantar/dorsi -
flexion trials.  This will be performed one leg at a time up to five times.  
- [ADDRESS_353385]:  The object of this test is to walk  as far as possible for [ADDRESS_353386] of the following tests:  
- Force Steadiness : For this test you will produce a submaximal force, 5%, 25% 
and 50% of your maximum strength, of your thigh muscles and hold for a period of [ADDRESS_353387] 4 stickers on your muscles designed to measure the electrical activity of your muscles while they are contracting.  
- Timed -Up-and-Go: For this test we will record the time it takes you to rise from a 
chair, walk [ADDRESS_353388] approximately 120- 180 minutes.  
    
 
Page 3 of 6 Participantâ€™s initials _______ Date _______   
Version 12May2017 
 
 CSU#: 16 -6685HH 
APPROVED:  6/15/2017 * EXPI[INVESTIGATOR_152617]: 6/14/2018   
 
ARE THERE REASONS WHY I SHOULD NOT TAKE PART IN THIS STUDY?  
You should not take part in this study if:  
 
â€¢ A relap se of disease sym ptoms i n the last 60 days  
â€¢ A condition unrelat ed to M S that would exacerbate fatigue , such as  
anemi a, hypothyroidism , shiftwork-related f atigue, B12 deficiency , 
major slee p disorder, o r maj or depr essive disorder  
â€¢ Medi cal d iagnosis or conditi on that  makes participating i n exercise 
training dangerous , such  as major renal , pulmonary, hep atic, cardi ac, 
gastrointestin al, HIV , cancer (other than treated basal cell cancer) , other 
neurologi cal d isorders, or pregna ncy 
â€¢ History of heart attack or current diagnosis of cardiovascular disease 
â€¢ History of seiz ure di sorders (or on medications know n to 
lower seizure threshold), hydrocephal us (buildup of fluid in 
the brain) , or diabetes 
â€¢ Alcoh o l d ependen ce or abuse (>2 drinks/day) , or present  history 
(last six months) of dru g abuse 
â€¢ History of significan t traumatic brain injury or hydrocep halus 
â€¢ Pregnancy  
â€¢ Recent hospi[INVESTIGATOR_059] (withi n the last 3 months) or enf orced bed    
   rest/sede ntary stat e. 
 
WHAT ARE THE POSSIBLE RISKS AND DISCOMFORTS?  
It is not possible to identify all potential risks in research procedures, but the researcher(s) have taken reasonable safeguards to minimize any known and potential, but unknown, risks. 
  
Risks of Performing Motor Tasks  
 Generally, the procedures outlined for measuring force and muscle activity during the 
motor tasks are safe.  Nevertheless, there is potential for injury  (muscle strain), resulting 
from the maximal contractions.   There is a 0.01% chance of death (in people who have 
heart problems), a 0.02% risk of cardiac arrhythmias that would require you to go the hospi[INVESTIGATOR_307] (in people with heart problems), and a risk of an increase or decrease in blood pressure.  
 All contractions are voluntary and you can stop immediately if they experience any slight 
pain or discomfort.  Following participation, you may experience some muscle soreness.  
Muscle soreness tends to be more common for individuals who have not exercised recently.  Other risk factors may include increased feelings of anxiety and/or stress induced by [CONTACT_152644], which can lead to an increase in heart rate and blood 
pressure.   The electrodes that will be used to measure muscle activity could potentially 
    
 
Page 4 of 6 Participantâ€™s initials _______ Date _______   
Version 12May2017 
 
 CSU#: 16 -6685HH 
APPROVED:  6/15/2017 * EXPI[INVESTIGATOR_152617]: 6/14/[ADDRESS_353389] been used previously by [CONTACT_152645].    
ARE THERE ANY BENEFITS FROM TAKING PART IN THIS STUDY?  
There may be no direct benefit to you associated with this research. This study is  
designed for the researcher to learn more about the effects of medical marijuana use for 
symptom management related to your diagnosis of Multiple Sclerosis .  This study is not 
designed to treat any illness or to improve your health specifically .   
 
DO I HAVE TO TAKE PART IN THE STUDY?  
Your participation in this research is voluntary.  If you decide to participate in the study, 
you may withdraw your consent and stop participating at any time.  
 WHAT WILL IT COST ME TO PARTICIPATE?  
Other than transport to and from the lab, your participation should incur no costs.  
 
WHO WILL SEE THE INFORMATION THAT I GIVE?  
We will keep private all research records that identify you, to the extent allowed by [CONTACT_2371].   
Your information will be combined with information from other people taking part in the study.  When we write about the study to share with other researchers, we will write 
about the combined information we have gathered.  You
 will not be identified in these 
written materials.  We may publish the results of this study; however, we will keep your 
name [CONTACT_56556]. 
 We will make every effort to prevent anyone who is not on the research team from knowing that you gave us information, or what that information is.  For example, your name [CONTACT_152664].  You should know, however, that there are some circumstances in which we may have to show your information to other people.   
We may be asked to share the research files with the CSU Institutional Review Board ethics committee for auditing purposes, if necessary.  
 
CAN MY TAKING PART IN THE STUDY END EARLY?  
If you fail to show up to your visits you may  be removed from the study.  
 WILL I RECEIVE ANY COMPENSATION FOR TAKING PART IN THIS STUDY?  
    
 
Page 5 of 6 Participantâ€™s initials _______ Date _______   
Version 12May2017 
 
 CSU#: 16 -6685HH 
APPROVED:  6/15/2017 * EXPI[INVESTIGATOR_152617]: 6/14/2018  Yes, you will receive $20, $25, and $[ADDRESS_353390] 
visits, respectively. 
 
WHAT HAPPENS IF I AM INJURED BECAUSE OF THE RESEARCH?  
The Colorado Governmental Immunity Act determines and may limit Colorado State 
University's legal responsibility if an injury happens because of this study.  Claims 
against the University must be filed within 180 days of the injury.  The research team will 
not cover any injury resulting in this study. You and/or your health insurance will be responsible for paying for any study -related injury.  
 FUTURE STUDIES:  
Would you like to be contact[CONTACT_152647]? Please 
initial:       Yes    No 
 WHAT IF I HAVE QUESTIONS?       
Before you decide whether to accept this invitation to take part in the study, please ask any questions that might come to mind now.  Later, if you have questions about the study, you can contact [CONTACT_093], [CONTACT_152674], via phone 970- 491-8655 or 
email: [EMAIL_3136].  If you have any questions about your rights as a volunteer in this research, contact [CONTACT_152646]:  RICRO_IRB@m ail.colostate.edu; 
[PHONE_3429]. We will give you a copy of this consent form to take with you.  
 
WHAT ELSE DO I NEED TO KNOW?  
 
A description of this clinical trial will be available on http://www.ClinicialTrials.gov
, as 
required by U.S. Law.  This website will not include information that can identify you.  At most, the website will include a summary of the results.  You can search this website at 
anytime.  
   
Your signature [CONTACT_152665].  Your signature [CONTACT_152666], on the date signed, a copy of this document containing    5     pages.  
 _________________________________________  _____________________  
Signature [CONTACT_152667]  
 _________________________________________  _____________________  
Printed name [CONTACT_152668]  
 _______________________________________   _____________________  
Name [CONTACT_152669]  
 _________________________________________    
    
 
Page 6 of 6 Participantâ€™s initials _______ Date _______   
Version 12May2017 
 
 CSU#: 16 -6685HH 
APPROVED:  6/15/2017 * EXPI[INVESTIGATOR_152617]: 6/14/2018  Signature [CONTACT_289674] 1 of 5 Participantâ€™s initials _______ Date _______   
Version 12May2017 CSU#: 16 -6685HH 
APPROVED: 6/15/2017  * EXPI[INVESTIGATOR_152617]: 6/14/2018  Consent to Participate in a Research Study  
Colorado State University  
 
TITLE OF STUDY: Medical marijuana and its effects on motor function in people 
with Multiple Sclerosis: An observational case- control study.  
 
 PRINCIPAL INVESTIGAT ORS:   
The principal investigator  [CONTACT_832] a researcher  in the Department of Health and Exercise 
Science at Colorado State University : 
 
Thorsten Rudroff, Ph.D. , FACSM       
[EMAIL_5670]
     
[PHONE_3428]         
 
WHY AM I BEING INVITED TO TAKE PART IN THIS RESEARCH?  
You are an adult aged between 30 and 60 years  of age, and you were diagnosed with 
Multiple Sclerosis.  
 WHO IS DOING THE STUDY?  
Dr. R udroff and the Integrative Neurophysiology Laboratory students/research staff . 
 
WHAT IS THE PURPOSE OF THIS STUDY?  
The purpose of this study is to determine possible benefits and consequences 
associated with medical marijuana use for the management of symptoms related to a 
diagnosis of Multiple Sclerosis .  
 
WHERE IS THE STUDY GOING TO TAKE PLACE AND HOW LONG WILL IT LAST?  
The study will take place in the Integrative Neurophysiology Laboratory  in the 
Department of Health and Exercise Science, on the Colorado State University  campus . 
The study will run for approximately 12 months. You will take part in the study for 
approximately  a total of 8 hours  over the spa n of three week s. 
 
WHAT WILL I BE ASKED TO DO?   
You will be asked to participate i n two sessions on two different days:  
 
Visit [ADDRESS_353391] visit will include the following procedures and tests:  
- Urinalysis : We will ask you to provide a urine sample for the confirmation of your 
research group assignment.  
- Questionnaires:  You will be asked to  complete a series of questionnaires to 
determine your fatigue levels, perceived risk  of fall ing, mood, and quality of life.   
- Resting Metabolic Rate: You will lay comfortably on a bed while we capture the 
air you are breathing out. Will analysis this air to determine how many calories you typi[INVESTIGATOR_289656], proteins, or fats are your primary sources for energy generation.  
    
 
Page 2 of 5 Participantâ€™s initials _______ Date _______   
Version 12May2017 CSU#: 16 -6685HH 
APPROVED: 6/15/2017  * EXPI[INVESTIGATOR_152617]: 6/14/2018  - Handgrip Strength:  We will measure your maximal handgrip strength using a 
device which you have to squeeze alternately with your left and right hand up to 
five times.  
- Medical Marijuana Use : We will give you a log to track your medical marijuana 
usage over the next 7 days.  
- Physical Activity:  At the end of the first session, you will be introduced to the 
ActiGraph device, which will measure physical activity.  You will be asked to wear 
this device on your waist  for a period of seven days (five week days and two 
weekend days). You can remove the ActiGraph at night.  You will be asked to return the ActiGraph at your second experimental session, which will be at least seven days after the first session.   Furthermore, you will receive a log to track 
their wear time.   
 
This visit will last approximately 120- [ADDRESS_353392] of the following tests : 
- MS Functional Composite : This is a series of [ADDRESS_353393] you add (+) a series of numbers spoken on a computer.  
- Balance test. In this test you will stand on a platform with your feet next to each 
other. You will stand quietly for 30 seconds in 4 different conditions: eyes open, eyes closed, eyes open on a foam pad, and eyes closed on a foam pad.  
- Leg Strength:  The maximal strength of each leg will be measured by [CONTACT_152643] a series of maximal effort knee extension, knee flexion, plantar/dorsi -
flexion trials.  This will be performed one leg at a time up to five times.  
- [ADDRESS_353394]:  The object of this test is to walk as far as possible for [ADDRESS_353395] of the following tests:  
- Force Steadiness : For this test you will produce a submaximal force, 5%, 25% 
and 50% of your maximum strength, of your thigh muscles and hold for a period of [ADDRESS_353396] 4 stickers on your muscles designed to measure the electrical activity of your muscles while they are contracting.  
- Timed -Up-and-Go: For this test we will record the time it takes you to rise from a 
chair, walk 3 meters, and return to the position you started in.  
 
    
 
Page 3 of 5 Participantâ€™s initials _______ Date _______   
Version 12May2017 CSU#: 16 -6685HH 
APPROVED: 6/15/2017  * EXPI[INVESTIGATOR_152617]: 6/14/[ADDRESS_353397] approximately 120- 180 minutes.  
 
ARE THERE REASONS WHY I SHOULD NOT TAKE PART IN THIS STUDY?  
You should not take part in this study if:  
 
â€¢ A relap se of disease sym ptoms i n the last 60 days  
â€¢ A condition unrelat ed to M S that would exacerbate fatigue , such as  
anemi a, hypothyroidism , shiftwork-related f atigue, B12 deficiency , 
major slee p disorder, o r maj or depr essive disorder  
â€¢ Medi cal d iagnosis or conditi on that  makes participating i n exercise 
training dangerous , such  as major renal , pulmonary, hep atic, cardi ac, 
gastrointestin al, HIV , cancer (other than treated basal cell cancer) , other 
neurologi cal d isorders, or pregna ncy 
â€¢ History of heart attack or current diagnosis of cardiovascular disease 
â€¢ History of seiz ure di sorders (or on medications know n to 
lower seizure threshold), hydrocephal us (buildup of fluid in 
the brain) , or diabetes 
â€¢ Alcoh o l d ependen ce or abuse (>2 drinks/day) , or present  history 
(last six months) of dru g abuse 
â€¢ History of significan t traumatic brain injury or hydrocep halus 
â€¢ Pregnancy  
â€¢ Recent hospi[INVESTIGATOR_059] (withi n the last 3 months) or enf orced bed    
   rest/sede ntary stat e. 
 
WHAT ARE THE POSSIBLE RISKS AND DISCOMFORTS?  
It is not possible to identify all potential risks in research procedures, but the researcher(s) have taken reasonable safeguards to minimize any known and potential, but unknown, risks. 
 
Risks of Performing Motor Tasks  
 Generally, the procedures outlined for measuring force and muscle activity during the motor tasks are safe.  Nevertheless, there is potential for injury  (muscle strain), resulting 
from the maximal contractions.   There is a 0.01% chance of death (in people who have 
heart problems), a 0.02% risk of cardiac arrhythmias that would require you to go the hospi[INVESTIGATOR_307] (in people with heart problems), and a risk of an increase or decrease in blood pressure.  
 All contractions are voluntary and you can stop immediately if they experience any slight 
pain or discomfort.  Following participation, you may experience some muscle soreness.  
Muscle soreness tends to be more common for individuals who have not exercised recently.  Other risk factors may inc lude increased feelings of anxiety and/or stress 
induced by [CONTACT_152644], which can lead to an increase in heart rate and blood pressure.   The electrodes that will be used to measure muscle activity could potentially 
cause skin irritation after removal.  Furthermore, your skin will need to be shaved prior 
to placing the electrodes, which can also cause irritation.  
    
 
Page 4 of 5 Participantâ€™s initials _______ Date _______   
Version 12May2017 CSU#: 16 -6685HH 
APPROVED: 6/15/2017  * EXPI[INVESTIGATOR_152617]: 6/14/[ADDRESS_353398] been used previously by [CONTACT_152645].   
 
ARE THERE ANY BENEFITS FROM TAKING PART IN THIS STUDY?  
There may be no direct benefit to you associated with this research. This study is  
designed for the researcher to learn more about the effects of medical marijuana use for 
symptom management related to your diagnosis of Multiple Sclerosis .  This study is not 
designed to treat any illness or to improve your health specifically .   
 
DO I HAVE TO TAKE PART IN THE STUDY?  
Your participation in this research is voluntary.  If you decide to participate in the study, 
you may withdraw your consent and stop participating at any time.  
 WHAT WILL IT COST ME TO PARTICIPATE?  
Other than transport to and from the lab, your participation should incur no costs. 
 
WHO WILL SEE THE INFORMATION THAT I GIVE?  
We will keep private all research records that identify you, to the extent allowed by [CONTACT_2371].   
Your information will be combined with information from other people taking part in the 
study.  When we write about the study to share with other researchers, we will write 
about the combined information we have gathered.  You
 will not be identified in these 
written materials.  We may publish the results of this study; however, we will keep your 
name [CONTACT_56556]. 
 
We will make every effort to prevent anyone who is not on the research team from knowing that you gave us information, or what that information is.  For example, your name [CONTACT_289675].  You should know, however, that there are some circumstances in which we may have to show your information to other people.   
We may be asked to share the research files with the CSU Institutional Review Board 
ethics committee for auditing purposes, if necessary.  
 
 
CAN MY TAKING PART IN THE STUDY END EARLY?  
If you fail to show up to your visits you may  be removed from the study.  
 
WILL I RECEIVE ANY COMPENSATION FOR TAKING PART IN THIS STUDY?  
Yes, you will receive $20, $25, and $[ADDRESS_353399] 
visits, respectively. 
    
 
Page 5 of 5 Participantâ€™s initials _______ Date _______   
Version 12May2017 CSU#: 16 -6685HH 
APPROVED: 6/15/2017  * EXPI[INVESTIGATOR_152617]: 6/14/2018   
WHAT HAPPENS IF I AM INJURED BECAUSE OF THE RESEARCH?  
The Colorado Governmental Immunity Act determines and may limit Colorado State 
University's legal responsibility if an injury happens because of this study.  Claims 
against the University must be filed within 180 days of the injury.  The research team will 
not cover any injury resulting in this study. You and/or your health insurance will be responsible for paying for any study -related injury.  
 FUTURE STUDIES:  
Would you like to be contact[CONTACT_152647]? Please 
initial:       Yes    No 
 WHAT IF I HAVE QUESTIONS?       
Before you decide whether to accept this invitation to take part in the study, please ask any questions that might come to mind now.  Later, if you have questions about the study, you can contact [CONTACT_093], [CONTACT_152674], via phone 970- 491-8655 or 
email: [EMAIL_3136].  If you have any questions about your rights as a volunteer in this research, contact [CONTACT_152646]:  RICRO_IRB@m ail.colostate.edu; 
[PHONE_3429]. We will give you a copy of this consent form to take with you.  
 
WHAT ELSE DO I NEED TO KNOW?  
 
A description of this clinical trial will be available on http://www.ClinicialTrials.gov
, as 
required by U.S. Law.  This website will not include information that can identify you.  At 
most, the website will include a summary of the results.  You can search this website at anytime.  
   
Your signature [CONTACT_152665].  Your signature [CONTACT_152666], on the date signed, a copy of this document containing    5     pages.  
 _________________________________________  _____________________  
Signature [CONTACT_152667]  
 _________________________________________  _____________________  
Printed name [CONTACT_152668]  
 _______________________________________   _____________________  
Name [CONTACT_152669]  
 _________________________________________    
Signature [CONTACT_289676] (Standard Deviation) unless otherwise noted. Pearsonâ€™s correlations 
were calculated between demographic variables (age, height, weight, BMI, disease duration) and whole 
brain SUV to identify possible covariates for the SPM analysis. Significant factors were individually 
tested as covariates during SPM analysis.  
 
Demographic, clinical, and extracted regional SUV variables were compared between the two 
groups using unpaired studentâ€™s t- tests. If a clinical variable differed between the two groups a Pearsonâ€™s 
correlation was performed with it and regional SUVs. Cohenâ€™s D measures of effect size were calculated 
for the regional SUVs. Analysis was performed using IBM SPSS Statistics for Windows version 24 (IBM 
Corp., NY, [LOCATION_003]) with alpha set to 0.05.  
 
 